In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...

NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose ...

On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid ...

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a ...

Rybrevant (amivantamab) - originally developed by Danish biotech Genmab – has been cleared for NSCLC patients with exon 20 insertions, the third most common EGFR mutation in this form of lung ...

Bispecific antibodies (bsAbs) are engineered to target 2 different epitopes simultaneously. About 75% of the 16 clinically ...

Prime Minister Netanyahu warned Iran of severe consequences for its missile attacks on Israel, emphasizing Israel's determination to retaliate decisively. Information ...

ASP-2138 is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip ...

Prime Minister Benjamin Netanyahu said Israel would retaliate against Iran after Tuesday’s missile attack. President Biden said he supported Israel’s right to defend itself but urged it not to ...

CNN anchor Jim Acosta cut short an interview with Corey Lewandowski after he repeatedly mispronounced Vice President Kamala Harris’ name despite being corrected. The discussion grew heated over ...